Pioneering a novel class of immunotherapy
EnnoDC I About
EnnoDC is a clinical-stage biotech that designs and develops a novel class of immunotherapy antibodies called Dendritic Cell engagers.
Learn More
EnnoDC I Science
By allowing simultaneously antigen-priming and controlled activation of dendritic cells in-vivo, DC engagers induce a precise, broad and durable immune response in patients with toughest cancer or viral infection.
EnnoDC I Pipeline
Our unique plug-and-play DC engagers studio has fueled a dynamic pipeline of 5 antibody candidates.
After a first clinical validation in HIV and COVID-19, the company is now advancing two programs in HPV16+ oropharyngeal and prostate cancer.
Learn More
